This article was originally published in The Gray Sheet
Cigna is the latest major payer to cover Johnson & Johnson/DePuy Spine's Charité artificial lumbar disc, the firm announces July 25. Cigna, which provides health insurance to 47 million people, joins Kaiser Permanente and Aetna, among others, who cover use of the device to treat degenerative disc disease. CMS and other payers' hesitance to cover the device, particularly due to lack of long-term follow-up data, has slowed acceptance of the procedure in the United States (1"The Gray Sheet" June 4, 2007, p. 5). DePuy says five-year Charité data is expected to be published this year...
You may also be interested in...
CMS is proposing to extend its national non-coverage policy for Johnson & Johnson/DePuy's Charité to all current and future artificial lumbar discs
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.